Literature DB >> 11931352

Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier.

Abba J Kastin1, Victoria Akerstrom, Weihong Pan.   

Abstract

Glucagon-like peptide-1 (GLP-1) reduces insulin requirement in diabetes mellitus and promotes satiety. GLP-1 in the periphery (outside the CNS) has been shown to act on the brain to reduce food ingestion. As GLP-1 is readily degraded in blood, we focused on the interactions of [Ser8]GLP-1, an analog with similar biological effects and greater stability, with the blood-brain barrier (BBB). The influx of radiolabeled [Ser8]GLP-1 into brain has several distinctive characteristics: 1. A rapid influx rate of 8.867 +/- 0.798 x 10(4) mL/g-min as measured by multiple-time regression analysis after iv injection in mice. 2. Lack of self-inhibition by excess doses of the unlabeled [Ser8]GLP-1 either iv or by in situ brain perfusion, indicating the absence of a saturable transport system at the BBB. 3. Lack of modulation by short-term fasting and some other ingestive peptides that may interact with GLP-1, including leptin, glucagon, insulin, neuropeptide Y, and melanin-concentrating hormone. 4. No inhibition of influx by the selective GLP-1 receptor antagonist exendin(9-39), suggesting that the GLP-1 receptor is not involved in the rapid entry into brain. Similarly, there was no efflux system for [Ser8]GLP-1 to exit the brain other than following the reabsorption of cerebrospinal fluid (CSF). The fast influx was not associated with high lipid solubility. Upon reaching the brain compartment, substantial amounts of [Ser8]GLP-1 entered the brain parenchyma, but a large proportion was loosely associated with the vasculature at the BBB. Finally, the influx rate of [Ser8]GLP-1 was compared with that of GLP-1 in a blood-free brain perfusion system; radiolabeled GLP-1 had a more rapid influx than its analog and neither peptide showed the self-inhibition indicative of a saturable transport system. Therefore, we conclude that [Ser8]GLP-1 and the endogenous peptide GLP-1 can gain access to the brain from the periphery by simple diffusion and thus contribute to the regulation of feeding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11931352     DOI: 10.1385/JMN:18:1-2:07

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  28 in total

1.  Measurement of efflux rates from brain to blood.

Authors:  W A Banks; M B Fasold; A J Kastin
Journal:  Methods Mol Biol       Date:  1997

2.  Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.

Authors:  P J Larsen; M Tang-Christensen; J J Holst; C Orskov
Journal:  Neuroscience       Date:  1997-03       Impact factor: 3.590

3.  Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

Authors:  W O Creutzfeldt; N Kleine; B Willms; C Orskov; J J Holst; M A Nauck
Journal:  Diabetes Care       Date:  1996-06       Impact factor: 19.112

4.  Phe(13),Tyr(19)-melanin-concentration hormone and the blood-brain barrier: role of protein binding.

Authors:  A J Kastin; V Akerstrom; L Hackler; J E Zadina
Journal:  J Neurochem       Date:  2000-01       Impact factor: 5.372

5.  Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

Authors:  M Tang-Christensen; P J Larsen; R Göke; A Fink-Jensen; D S Jessop; M Møller; S P Sheikh
Journal:  Am J Physiol       Date:  1996-10

6.  Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.

Authors:  J P Gutzwiller; J Drewe; B Göke; H Schmidt; B Rohrer; J Lareida; C Beglinger
Journal:  Am J Physiol       Date:  1999-05

7.  Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung.

Authors:  S M Kanse; B Kreymann; M A Ghatei; S R Bloom
Journal:  FEBS Lett       Date:  1988-12-05       Impact factor: 4.124

8.  A synthetic glucagon-like peptide-1 analog with improved plasma stability.

Authors:  U Ritzel; U Leonhardt; M Ottleben; A Rühmann; K Eckart; J Spiess; G Ramadori
Journal:  J Endocrinol       Date:  1998-10       Impact factor: 4.286

9.  Functional interactions between melanin-concentrating hormone, neuropeptide Y, and anorectic neuropeptides in the rat hypothalamus.

Authors:  N A Tritos; D Vicent; J Gillette; D S Ludwig; E S Flier; E Maratos-Flier
Journal:  Diabetes       Date:  1998-11       Impact factor: 9.461

10.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Authors:  T J Kieffer; C H McIntosh; R A Pederson
Journal:  Endocrinology       Date:  1995-08       Impact factor: 4.736

View more
  139 in total

1.  The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction.

Authors:  Y Diz-Chaves; L Toba; J Fandiño; L C González-Matías; L M Garcia-Segura; F Mallo
Journal:  J Neuroinflammation       Date:  2018-12-05       Impact factor: 8.322

2.  Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates.

Authors:  Nicholas T Bello; Matthew H Kemm; Erica M Ofeldt; Timothy H Moran
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-06-16       Impact factor: 3.619

Review 3.  Concepts for biologically active peptides.

Authors:  Abba J Kastin; Weihong Pan
Journal:  Curr Pharm Des       Date:  2010-10       Impact factor: 3.116

Review 4.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 5.  Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy balance [corrected] and metabolism.

Authors:  Diego Perez-Tilve; Ruben Nogueiras; Federico Mallo; Stephen C Benoit; Matthias Tschoep
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 6.  Blood-brain barrier and feeding: regulatory roles of saturable transport systems for ingestive peptides.

Authors:  Abba J Kastin; Weihong Pan
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 7.  Central control of body weight and appetite.

Authors:  Stephen C Woods; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

8.  Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.

Authors:  Lene Jessen; Benedikt A Aulinger; Jonathan L Hassel; Kyle J Roy; Eric P Smith; Todd M Greer; Stephen C Woods; Randy J Seeley; David A D'Alessio
Journal:  Endocrinology       Date:  2012-10-02       Impact factor: 4.736

9.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

10.  GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents.

Authors:  Jianping Ye; Zheng Hao; Michael B Mumphrey; R Leigh Townsend; Laurel M Patterson; Nicholas Stylopoulos; Heike Münzberg; Christopher D Morrison; Daniel J Drucker; Hans-Rudolf Berthoud
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-01-15       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.